Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
New York, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research. The update note includes detailed information on the MAIA Biotechnology’s business, recent updates, management commentary, financial results, valuation, and risks.
The full update note is available below.
MAIA Biotechnology August 2026 Update Note
Highlights from the note include:
- Strong Phase 3 THIO-104 Enrollment Momentum Supports Visibility Toward Key 2027 Overall Survival Readout: With enrollment progressing across the pivotal Phase 3 THIO-104 trial, the company is targeting up to 100 patients by year-end and expects sufficient survival data to conduct an interim analysis in 2027. The trial is expected to randomize up to 300 third-line NSCLC patients on a 1:1 basis between ateganosine sequenced with a checkpoint inhibitor (CPI) and the investigator’s choice of chemotherapy, with median overall survival (OS) as the primary efficacy endpoint, and is designed to validate the 17.8-month median OS observed in Parts A and B of the Phase 2 THIO-101 trial, compared with the expected survival of 5.8 months with chemotherapy in a heavily pre-treated population. Continued enrollment momentum supports visibility toward the 2027 interim analysis, which could provide the first pivotal indication of whether the substantial survival signal observed in Phase 2 can be replicated in a randomized Phase 3 setting.
- Strong Phase 3 THIO-104 Enrollment Momentum Supports Visibility Toward Key 2027 Overall Survival Readout: With enrollment progressing across the pivotal Phase 3 THIO-104 trial, the company is targeting up to 100 patients by year-end and expects sufficient survival data to conduct an interim analysis in 2027. The trial is expected to randomize up to 300 third-line NSCLC patients on a 1:1 basis between ateganosine sequenced with a checkpoint inhibitor (CPI) and the investigator’s choice of chemotherapy, with median overall survival (OS) as the primary efficacy endpoint, and is designed to validate the 17.8-month median OS observed in Parts A and B of the Phase 2 THIO-101 trial, compared with the expected survival of 5.8 months with chemotherapy in a heavily pre-treated population. Continued enrollment momentum supports visibility toward the 2027 interim analysis, which could provide the first pivotal indication of whether the substantial survival signal observed in Phase 2 can be replicated in a randomized Phase 3 setting.
- Significant Clinical Progress with Expanded U.S. Enrollment, Advancing Trials and Enhanced Funding Visibility for Ateganosine: MAIA Biotechnology made notable progress across its ateganosine (THIO) development programs during Q2 2026, with the $33 million raised through its March financing expected to fully fund the ongoing pivotal Phase 3 THIO-104 trial in advanced third-line (3L) NSCLC. The Phase 2 THIO-101 expansion also advanced toward a broader U.S. recruitment base, with the first U.S. clinical site, Summit Medical Group in New Jersey, activated in April, followed by two additional U.S. sites in June, while four further sites are planned for 2026; this supplements 44 active sites across six countries internationally and provides access to a significantly larger patient pool. FDA clearance of the amended IND enabled U.S. patient enrollment and incorporated manufacturing updates, including additional manufacturers, formulation improvements, and revised storage conditions for ateganosine, supporting the program’s broader clinical deployment. Meanwhile, THIO-104 had 29 patients dosed across 34 activated sites in six countries outside the U.S. as of early June, while international enrollment in Part C of THIO-101 was completed by quarter-end, with patient screening continuing at activated U.S. sites and international outcomes and data continuing to mature.
- Completed International Enrollment in Phase 2 THIO-101 Part C and 90.5% Interim Disease Control Rate Strengthen Evidence of Ateganosine’s Consistent Clinical Activity in Third-Line NSCLC: MAIA Biotechnology completed international enrollment in Part C of the Phase 2 THIO-101 expansion trial, with 41 patients enrolled and receiving treatment following screening across Taiwan, Turkey, Poland, Hungary, Romania, and Georgia, while patient screening continued separately at three activated U.S. sites. Part C is evaluating ateganosine (THIO) in advanced third-line (3L) non-small cell lung cancer (NSCLC) patients resistant to prior checkpoint inhibitor (CPI) therapy and chemotherapy, with patients randomized between ateganosine followed by cemiplimab (Libtayo®) and ateganosine monotherapy for two cycles. Initial data as of July 6, 2026, showed a 90.5% interim disease control rate (DCR) in 19 of 21 efficacy-evaluable patients who had undergone at least one tumor scan after initiating treatment with ateganosine followed by cemiplimab in 21-day cycles, compared with an approximately 25–35% DCR reported for chemotherapy. The result is particularly notable given the difficult-to-treat population, with all Part C patients having previously received docetaxel and demonstrated resistance to both immunotherapy and other chemotherapies, yet the observed DCR remained broadly consistent with the 88% previously reported in third-line patients in Parts A and B. The broader THIO-101 dataset has also continued to demonstrate encouraging durability, with eight patients from Parts A and B surviving beyond two years without receiving subsequent lines of therapy and one third-line patient surviving for more than 33 months, while ateganosine followed by cemiplimab has maintained an acceptable safety profile to date in this heavily pre-treated population. We believe the consistency of disease control across separate THIO-101 cohorts, despite the greater prior treatment burden in Part C, alongside the continued maturation of long-term survival outcomes in Parts A and B, provides encouraging evidence of potentially reproducible and durable clinical activity. However, with only 21 of the 41 treated international Part C patients efficacy-evaluable at the initial cutoff, the 90.5% DCR remains an early signal, and longer follow-up and more mature response and survival data will be important to establish the depth and durability of benefit.
- Second Quarter 2026 Financial Results Update and Valuation - MAIA Biotechnology’s 2Q 2026 results continue to reflect the elevated investment profile typical of a late-stage clinical biotechnology company, with operating expenses increasing approximately 61% to $8.3 million as the company accelerates development of THIO. R&D expenses rose approximately 81% to $5.6 million, primarily reflecting increased clinical activity across the ongoing THIO-101 Phase 2 expansion and the pivotal THIO-104 Phase 3 program, while G&A expenses also increased as the organization scales to support broader clinical and regulatory execution. As a result, the quarterly net loss widened to approximately $7.9 million, while operating cash outflow for the first half of 2026 increased to $12.1 million from $8.3 million a year earlier. Despite the higher spending base, MAIA’s liquidity position improved substantially following the March 2026 public offering, with cash reaching approximately $27.6 million at June-end, providing greater financial flexibility to advance THIO through key upcoming development milestones.The quarter is therefore defined less by near-term earnings performance and more by continued de-risking of the company’s lead asset, supported by encouraging Phase 2 efficacy data, ongoing Phase 3 enrollment, and the potential for meaningful regulatory progress over the next two years. Accordingly, our valuation model continues to be driven primarily by the probability-adjusted commercial potential of THIO, while recognizing the remaining risks around clinical execution, regulatory approval, future capital requirements, and dilution. We continue to apply a 13.6% discount rate within our valuation framework. After incorporating the recent financial results together with an updated comparable-company assessment, we arrive at an illustrative valuation of $10.00 per share, subject to successful execution including clinical progression, regulatory clearance, and eventual commercialization of THIO.
About MAIA Biotechnology, Inc
Founded in 2018 and headquartered in Chicago, Illinois, MAIA is a biotechnology company engaged in discovering, developing, and commercializing novel cancer therapies with high unmet medical needs.
For more information, visit https://maiabiotech.com/
About Diamond Equity Research
Diamond Equity Research is a leading equity research and corporate access firm focused on small capitalization companies. Diamond Equity Research is an approved sell-side provider on major institutional investor platforms.
For more information, visit https://www.diamondequityresearch.com.
Disclosures:
Diamond Equity Research LLC is being compensated by MAIA Biotechnology, Inc. for producing research materials regarding MAIA Biotechnology, Inc. and its securities, which is meant to subsidize the high cost of creating the report and monitoring the security, however the views in the report reflect that of Diamond Equity Research. All payments are made in advance of each service provided and are billed for the research services under an annual engagement agreement. As of 08/17/26, the issuer paid us $129,500 in cash compensation for research services that continue only if mutually agreed in writing by both parties. Payments were made as follows: $20,000 for an initiation report and $15,000 for update notes in the first year; $20,000 for one update note and $11,500 for three follow-on notes in the second year; $20,000 for one update note and $11,500 for three follow-on notes in the third year; and $20,000 for one update note and $11,500 for three follow-on notes in the fourth year. Research services commenced and initiation payment was made on 11/10/22. Additional compensation may be received in future years if the engagement is renewed. Diamond Equity Research LLC may be compensated for non-research related services, including presenting at Diamond Equity Research investment conferences, press releases and other additional services. The non-research related service cost is dependent on the company, but usually do not exceed $5,000. The issuer has not paid us for non-research-related services as of 08/17/26. Issuers are not required to engage us for these additional services. Additional fees may have accrued since then. Although Diamond Equity Research company sponsored reports are based on publicly available information and although no investment recommendations are made within our company sponsored research reports, given the small capitalization nature of the companies we cover we have adopted an internal trading procedure around the public companies by whom we are engaged, with investors able to find such policy on our website public disclosures page. This report and press release do not consider individual circumstances and does not take into consideration individual investor preferences.This report is based on information we consider reliable, including the subject of the report. This report does not explicitly or implicitly affirm that the information contained in this document is accurate and/or comprehensive, and as such should not be relied on in such capacity. All information contained within this report is subject to change without any formal or other notice provided. Statements within this report may constitute forward-looking statements, these statements involve many risk factors and general uncertainties around the business, industry, and macroeconomic environment. Investors need to be aware of the high degree of risk in small capitalization equities including the complete potential loss of their investment. Investors can find various risk factors in the initiation report and in the respective financial filings for MAIA Biotechnology, Inc. Please review update report attached for full disclosures.
Attachment
Diamond Equity Research research@diamondequityresearch.com
© Copyright Globe Newswire, Inc. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire, Inc.
